NASDAQ | ETF
Top 12 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| LLY | Eli Lilly and Company | Healthcare | Drug Manufacturers - General | 14.73% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 7.88% |
| BMY | Bristol-Myers Squibb Company | Healthcare | Drug Manufacturers - General | 5.43% |
| AMGN | Amgen Inc | Healthcare | Drug Manufacturers - General | 5.38% |
| NVS | Novartis AG ADR | Healthcare | Drug Manufacturers - General | 5.23% |
| JNJ | Johnson & Johnson | Healthcare | Drug Manufacturers - General | 5.14% |
| MRK | Merck & Company Inc | Healthcare | Drug Manufacturers - General | 5% |
| AZN | AstraZeneca PLC ADR | Healthcare | Drug Manufacturers - General | 4.77% |
| BIIB | Biogen Inc | Healthcare | Drug Manufacturers - General | 4.59% |
| CRSP | Crispr Therapeutics AG | Healthcare | Biotechnology | 4.06% |
| PFE | Pfizer Inc | Healthcare | Drug Manufacturers - General | 4.05% |
| REGN | Regeneron Pharmaceuticals Inc | Healthcare | Biotechnology | 3.9% |
The fund is an actively-managed exchange-traded fund ("ETF") that pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries. The fund is non-diversified.